Struggling With Depression?

Spravato® (esketamine) nasal spray is an FDA-approved treatment for adults with treatment-resistant (refractory) depression. Fountain Valley Healthcare provides compassionate, evidence-based Spravato treatment in a safe, monitored clinical setting. 

Spravato® is a prescription nasal spray used in combination with an oral antidepressant for adults who have not experienced adequate relief after trying two or more antidepressant medications.

Unlike traditional antidepressants, Spravato works through a different mechanism in the brain and may provide faster symptom relief for some patients.

You may be a candidate if you:

• Have been diagnosed with Major Depressive Disorder (MDD)
• Have tried two or more antidepressants without adequate improvement
• Continue to experience significant depressive symptoms
• Are able to attend in-office treatment and monitoring

A comprehensive psychiatric evaluation is required to determine eligibility.

• Spravato is administered as a nasal spray in our clinic
• Treatment is provided by REMS-certified healthcare professionals
• Patients are monitored on-site for at least 2 hours after each treatment
• You must arrange transportation home after treatment

Typical Treatment Schedule

• Induction phase: Usually twice weekly for the first 4 weeks then once a week for 4 weeks
• Maintenance phase: Frequency may decrease based on your response

Spravato is covered by most major insurance plans, including:

• Commercial insurance plans (BCBS, Aetna, Cigna, UnitedHealthcare)
• Medicare and many Medicare Advantage plans
• Medicaid plans 

Insurance approval typically requires documentation of treatment-resistant depression and prior authorization. Our staff can assist with insurance verification and authorization.

There are also options for uninsured patients.